window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 18, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Central Nervous System

  • Central Nervous System,Clinical Development,Drug Delivery & Formulation,Drug Development,Neurosciences,Patient Centricity

    Emalex secures US patent for ecopipam orally disintegrating tablet in Tourette syndrome

    Emalex Biosciences has secured a US patent for an orally [...]

    April 11, 2026
  • Central Nervous System,Mental health,Neurosciences,Research & Development

    Strategies to extend ketamine antidepressant effects identified in new study

    Researchers have identified a molecular target that could extend the [...]

    March 31, 2026
  • Central Nervous System,Clinical Development,Clinical studies,Global health,Neurosciences,Research & Development,Women's Health

    International Brain Health Conference 2026 to focus on early intervention before dementia

    The inaugural International Brain Health Conference 2026 in Edinburgh will [...]

    February 19, 2026
  • Biotech,Central Nervous System,Clinical Development,Drug Development,Rare Diseases,Research & Development

    Lario receives $2.4M from MJFF and Wellcome to expand neuronal calcium channel research in CNS disorders

    Lario Therapeutics awarded $2.4M by The Michael J. Fox Foundation [...]

    February 19, 2026
  • Central Nervous System,Clinical Development,Clinical Trials,Funding

    Newron secures up to EUR 38 million to advance Phase 3 evenamide program in treatment-resistant schizophrenia

    Newron Pharmaceuticals has secured up to EUR 38 million in [...]

    February 16, 2026
  • Artificial Intelligence,Biotech,Central Nervous System,Clinical Development,Drug Development,Immunology,Pharmaceuticals and therapeutics,Technology and platforms

    Insilico Medicine and CMS announce AI-powered drug discovery collaborations in CNS and autoimmune diseases

    Insilico Medicine and China Medical System Holdings Limited (CMS) have [...]

    February 15, 2026
  • Central Nervous System,Clinical Development,Movers & Shakers,Neurosciences,Pharmaceuticals and therapeutics

    Oryzon appoints Rolando Gutierrez-Esteinou as chief medical officer for CNS programs

    Oryzon Genomics has appointed Rolando Gutierrez-Esteinou, as chief medical officer [...]

    February 15, 2026
  • Central Nervous System,Clinical Development,Clinical Trials,Drug Development,FDA,Pharmaceuticals and therapeutics,Precision medicine,Research & Development

    Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in cognitive impairment associated with schizophrenia

    Alto Neuroscience has completed patient enrollment in its Phase 2 [...]

    February 13, 2026
  • Central Nervous System,Chronic diseases,Clinical Development,Clinical Trials,Drug Delivery & Formulation,Drug Development,Pharmaceuticals and therapeutics,Respiratory

    Positive Phase 3 KALOS and LOGOS trial results for Breztri published in The Lancet Respiratory Medicine

    Full results from the Phase 3 KALOS and LOGOS trials [...]

    February 13, 2026
  • Central Nervous System,Clinical Development,Clinical studies,Mental health,Neurosciences,Pharmaceuticals and therapeutics

    Newron publishes data showing clinically meaningful benefits of evenamide in treatment-resistant schizophrenia

    Newron Pharmaceuticals has published peer-reviewed clinical data demonstrating that evenamide, [...]

    February 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top